MTNR1B rs10830963 G allele increases type 2 diabetes risk.

The association between the MTNR1B rs10830963 G allele and metabolic dysfunction is one of the most robustly established findings in the genetics of type 2 diabetes (T2D). This variant specifically targets the intersection of circadian rhythms and pancreatic function, creating a distinct physiological profile characterized by elevated fasting glucose and impaired early insulin response.

Clinical and effectiveness evidence

Research consistently identifies the G allele as a primary driver of glycemic variability and diabetes risk:

• Fasting Glucose: Meta-analyses show the G allele is strongly associated with higher fasting plasma glucose (FPG) levels, with effect sizes ranging from 0.072 mmol/L to 0.17 standardized beta per allele.
• Diabetes Risk: Large-scale cohort studies, including the UK Biobank (n=283,531), report a significant increase in T2D risk. Odds ratios (OR) typically range from 1.05 to 1.73 per G allele.
• Independence from BMI: This risk remains significant after adjusting for Age, Sex, and Body Mass Index (BMI), indicating that the G allele influences diabetes risk through mechanisms independent of obesity or adiposity.

Mechanistic explanations

The rs10830963 G allele is a functional variant that alters the expression of the melatonin receptor 1B (MT2) in the pancreas:

• Increased Receptor Expression: The G allele acts as an expression quantitative trait locus (eQTL), increasing MTNR1B mRNA and protein levels within human pancreatic islets.
• Inhibition of Insulin Release: MT2 is a G-protein-coupled receptor. When activated by melatonin, it reduces intracellular cAMP levels via Gi-coupled pathways. This suppresses adenylyl cyclase and protein kinase A (PKA) activity, which are essential for glucose-stimulated insulin secretion (GSIS).
• Secretory Defects: Carriers exhibit a specific impairment in early-phase insulin secretion (the insulinogenic index). This deficit is observed during both oral and intravenous glucose tolerance tests, while peripheral insulin sensitivity remains largely unaffected.

Bottom line

The MTNR1B rs10830963 G allele is a major genetic determinant of fasting glycemia. It increases type 2 diabetes risk by upregulating melatonin receptors in the pancreas, which suppresses the early insulin surge required to maintain glucose homeostasis.